Chardan Capital Remains Positive on Endocyte (ECYT) into 2014 ESMO Congress Sep 25, 2014 08:27AM
Chardan Capital Affirms Endocyte (ECYT) at Buy Following Q2 Results, Operational Update Jul 30, 2014 02:49PM
Chardan Capital Cuts PT on Endocyte (ECYT) to $15 After Regaining Vintafolide Rights Jun 18, 2014 08:28AM
Pre-Open Stock Movers 3/25: (GALT) (ECYT) (RAX) Higher; (IDN) (HIMX) (GIII) Lower (more...) Mar 25, 2014 09:27AM
Chardan Capital Markets Lifts Price Target on Endocyte (ECYT) Sharply Mar 25, 2014 08:09AM


Sep 30, 2013 09:06AM UPDATE: Chardan Capital Markets Starts Endocyte (ECYT) at Buy